The Amsterdam Cohort of Gender Dysphoria Study (1972–2015): Trends in Prevalence, Treatment, and Regrets

Chantal M. Wiepjes,1,2 Nienke M. Nota,1,2 Christel J. M. de Blok,1,2 Maartje Klaver,1,2 Annelou L. C. de Vries,2,3 S. Annelijn Wensing-Kruger,2,6 Renate T. de Jongh,1 Mark-Bram Bouman,2,5 Thomas D. Steensma,2,4 Peggy Cohen-Kettenis,2,4 Louis J. G. Gooren,1,2 Baudewijn P. C. Kreukels,2,4 and Martin den Heijer, MD, PhD1,2

ABSTRACT

Background: Over the past decade, the number of people referred to gender identity clinics has rapidly increased. This raises several questions, especially concerning the frequency of performing gender-affirming treatments with irreversible effects and regret from such interventions.

Aim: To study the current prevalence of gender dysphoria, how frequently gender-affirming treatments are performed, and the number of people experiencing regret of this treatment.

Methods: The medical files of all people who attended our gender identity clinic from 1972 to 2015 were reviewed retrospectively.

Outcomes: The number of (and change in) people who applied for transgender health care, the percentage of people starting with gender-affirming hormonal treatment (HT), the estimated prevalence of transgender people receiving gender-affirming treatment, the percentage of people who underwent gonadectomy, and the percentage of people who regretted gonadectomy, specified separately for each year.

Results: 6,793 people (4,432 birth-assigned male, 2,361 birth-assigned female) visited our gender identity clinic from 1972 through 2015. The number of people assessed per year increased 20-fold from 34 in 1980 to 686 in 2015. The estimated prevalence in the Netherlands in 2015 was 1:3,800 for men (transwomen) and 1:5,200 for women (transmen). The percentage of people who started HT within 5 years after the 1st visit decreased over time, with almost 90% in 1980 to 65% in 2010. The percentage of people who underwent gonadectomy within 5 years after starting HT remained stable over time (74.7% of transwomen and 83.8% of transmen). Only 0.6% of transwomen and 0.3% of transmen who underwent gonadectomy were identified as experiencing regret.

Clinical Implications: Because the transgender population is growing, a larger availability of transgender health care is needed. Other health care providers should familiarize themselves with transgender health care, because HT can influence diseases and interact with medication. Because not all people apply for the classic treatment approach, special attention should be given to those who choose less common forms of treatment.

Strengths and Limitations: This study was performed in the largest Dutch gender identity clinic, which treats more than 95% of the transgender population in the Netherlands. Because of the retrospective design, some data could be missing.

Conclusion: The number of people with gender identity issues seeking professional help increased dramatically in recent decades. The percentage of people who regretted gonadectomy remained small and did not show a tendency to increase. Wiepjes CM, Nota NM, de Blok CJM, et al. The Amsterdam Cohort of Gender Dysphoria Study (1972–2015): Trends in Prevalence, Treatment, and Regrets. J Sex Med 2018;XX:XXX–XXX.

Copyright © 2018, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Key Words: Transgender; Prevalence; Regret; Gender-Affirming Hormones; Gender-Affirming Surgery
INTRODUCTION

Gender dysphoria (GD) refers to the distress related to a marked incongruence between one’s assigned sex at birth and the experienced gender later in life.1 In this study, we define transgender people as having a male birth assignment and transmen as having a female birth assignment who might receive medical treatment to adapt their physical characteristics to their experienced gender. This treatment can include puberty suppression (PS), gender-affirming hormonal treatment (HT), and gender-affirming surgery.

It has been widely observed that the transgender population is growing and broadening.2,3 This increase in the transgender population raises several questions, especially concerning the frequency of performing gender-affirming treatments with irreversible effects and regret from such interventions.

There are no reliable estimations of the current prevalence of transgender people who actually have received gender-affirming treatment (including HT), because most recent studies are based on questionnaires4,5 or data about gender-affirming surgery only.6,7 In most countries transgender care is performed by multiple health care providers (eg, university clinics or general practitioners), which makes it difficult to provide these numbers. In contrast, in the Netherlands, more than 95% of the transgender population has received treatment in only 1 center, the gender identity clinic of the VU University Medical Center (VUmc; Amsterdam, the Netherlands), currently known as the Center of Expertise on Gender Dysphoria.8–10 This center started treating adults in 1972. From 1987 to 2002, children and adolescents were seen by a mental health specialist in the Utrecht University Medical Center (Utrecht, the Netherlands). After they were considered eligible, they could receive medical treatment in the VUmc, which consisted of PS (usually by gonadotropin-releasing hormone analogues), followed by HT (see Kreukels and Cohen-Kettenis11 for the treatment protocol for adolescents diagnosed with GD). After 2002, the Utrecht clinic stopped seeing adolescents and the diagnostics were performed in the VUmc. Adult people are referred to a psychologist or psychiatrist for the diagnostic phase after an initial screening. People diagnosed with GD can start HT if they are considered eligible. HT consists of testosterone for transmen and estrogens, often combined with antiandrogens, for transwomen. In the 1st year of HT, checkups are performed every 3 months. After a minimum of 12 months of HT, gender-affirming surgery can be performed, including mastectomy and hysterectomy with oophorectomy in transmen and breast augmentation and vaginoplasty (including orchiectomy) in transwomen. After gonadectomy (oophorectomy or orchiectomy), people are usually seen every 1 to 2 years for clinical follow-up.

In the present study we included the complete population seen at the gender identity clinic of the VUmc from 1972 through December 2015 to assess the current prevalence of transgender people who received medical treatment, the frequency of specific medical treatments performed, and the numbers of people who received HT in line with their sex assigned at birth because they regretted undergoing gonadectomy.

METHODS

Study Design and Patient Selection

After approval of the local ethics committee, a retrospective medical record review was performed to identify all people seen in our gender identity clinic from 1972 until December 2015. Data were collected from the hospital registries of the VUmc. The total study population was defined as people who had been diagnosed with 1 of the following International Classification of Diseases diagnoses: 302.5 (transsexualism), 302.6 (gender identity disorder not otherwise specified), or 302.85 (gender identity disorder in adolescent or adult) according to the 9th edition or F64 (gender identity disorders) according to the 10th edition.12 In addition, the administrative employees of our gender identity clinic registered everyone who was referred to our gender identity clinic since the early 1970s. People reported on this list also were included in the study population. Some people of this study population have been described in previous studies.9,13–18 People were excluded from the study if they had been registered at our gender identity clinic but had actually never visited the clinic or if they had presented with other complaints than gender identity issues. Because of the retrospective design and the large study population, necessity for informed consent was waived by our local ethics committee.

Hospital Registries

The hospital registries store clinical data obtained during regular patient care performed in our center, including medical diagnoses (since 1985), medication prescriptions (since 2000), surgical interventions (since 2006), laboratory test results (since 2004), radiology results (since 1993), and visit dates (since 2007). The 1st visit was defined as the 1st appointment with the psychologist, psychiatrist, pediatrician, endocrinologist, or gynecologist for health care related to gender identity.

Clinical Data Collection

Not all data were available from the hospital registries, particularly older data or surgeries performed in other centers. To generate the most reliable results, the medical records of all people who composed the study population were checked. All people were classified as transwomen or transmen (based on the sex assigned at birth), and date of birth and death were noted. The following categories were included: the individual was in the diagnostic stage, the individual did not start HT, or the individual was on HT. Start of HT was defined as the 1st date gender-affirming hormones were prescribed by a physician in our gender identity clinic after a confirmed GD diagnosis, irrespective of previous gender-affirming hormone use. Of the people who started HT, baseline and follow-up data, including
1st visit, medical history, medication use, prior gender-affirming hormone use, start date and type of PS and HT, and date of gonadectomy, were collected. Some people regretted the interventions they had undergone. Transwomen who started testosterone treatment after vaginoplasty or transmen who started estrogen treatment after oophorectomy and expressed regret were categorized as those who experienced regret. Reasons for regret as reported in their medical records were noted. Dates were set to categorized as those who experienced regret. Reasons for regret as estimated for surgery. People who regretted their medical transition are reported as the percentage of the total population of transwomen and transmen who underwent gonadectomy. In adults, time from 1st visit to start of HT or gonadectomy, if applicable, are expressed as median days with interquartile range (IQR). Total follow-up time was calculated for every individual who started HT and was expressed as years from the 1st visit to the last visit. Prevalence with 95% CI was calculated using OpenEpi. All other analyses were performed using STATA 13.1 (StataCorp, College Station, TX, USA).

**RESULTS**

**1st Visit**

6,793 people presented for gender-affirming treatment, with more transwomen (65.2%) than transmen (34.8%; Table 1). The number of people attending the gender identity clinic increased over time (Table 2), whereas the median age of adults at the time of their 1st visit decreased (Figure 1). The median age at the 1st visit was younger for adult transmen (25 years; IQR = 21–35 years) than for adult transwomen (33 years; IQR = 25–42 years). Although historically more transwomen than transmen presented for treatment, more transmen than

**Table 1. Treatment patterns of total study population, stratified for age groups and for transwomen and transmen***

<table>
<thead>
<tr>
<th></th>
<th>Transwomen</th>
<th>Transmen</th>
<th>Total</th>
<th>Ratio of transwomen to transmen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total study population, N (%)</td>
<td>4,432 (65.2)</td>
<td>2,361 (34.8)</td>
<td>6,793 (100)</td>
<td>1.9:1</td>
</tr>
<tr>
<td>Adults (&gt;18 y)</td>
<td>3,809</td>
<td>1,624</td>
<td>5,433</td>
<td>2.3:1</td>
</tr>
<tr>
<td>Age (y), median (IQR; max)</td>
<td>33 (25–42; 81)</td>
<td>25 (21–35; 73)</td>
<td>31 (23–4; 81)</td>
<td></td>
</tr>
<tr>
<td>Started HT†, %</td>
<td>68.9</td>
<td>72.9</td>
<td>69.9</td>
<td></td>
</tr>
<tr>
<td>Underwent gonadectomy‡, %</td>
<td>75.3</td>
<td>83.8</td>
<td>77.7</td>
<td></td>
</tr>
<tr>
<td>Adolescents (12–18 y)</td>
<td>330</td>
<td>482</td>
<td>812</td>
<td>0.7:1</td>
</tr>
<tr>
<td>Age (y), median (IQR)</td>
<td>16 (15–17)</td>
<td>16 (15–17)</td>
<td>16 (15–17)</td>
<td></td>
</tr>
<tr>
<td>Started PS§, %</td>
<td>28.7</td>
<td>50.8</td>
<td>41.0</td>
<td></td>
</tr>
<tr>
<td>Stopped PS, %</td>
<td>4.1</td>
<td>0.7</td>
<td>1.9</td>
<td></td>
</tr>
<tr>
<td>Started HT§ without PS, %</td>
<td>33.9</td>
<td>30.8</td>
<td>32.2</td>
<td></td>
</tr>
<tr>
<td>Underwent gonadectomy§, %</td>
<td>79.5</td>
<td>77.2</td>
<td>78.2</td>
<td></td>
</tr>
<tr>
<td>Children (&lt;12 y)</td>
<td>293</td>
<td>255</td>
<td>548</td>
<td>1.1:1</td>
</tr>
<tr>
<td>Age (y), median (IQR)</td>
<td>8 (7–10)</td>
<td>9 (8–11)</td>
<td>9 (7–10)</td>
<td></td>
</tr>
<tr>
<td>Started PS⊥, %</td>
<td>33.6</td>
<td>49.1</td>
<td>40.3</td>
<td></td>
</tr>
<tr>
<td>Regret*, % (n)</td>
<td>0.6 (11)</td>
<td>0.3 (3)</td>
<td>0.5 (14)</td>
<td>2.0:1</td>
</tr>
</tbody>
</table>

HT = gender-affirming hormonal therapy; IQR = interquartile range; max = maximum; PS = puberty suppression.

*From 1987 through 2002, children and adolescents were seen at the Utrecht University Medical Center and then at the VU University Medical Center only if they could begin medical treatment.
†Age is defined as the age at the 1st visit to the VU University Medical Center, Amsterdam.
‡Only those who reached the age of eligibility (usually ≥12 years old) could undergo PS.
§Only men in people at least 16 years old.
⊥Only people treated with gender-affirming hormones for at least 1.5 years and at least 18 years old (orchiectomy in transwomen and oophorectomy in transmen).
*Those who were too old (≥18 years) after the diagnostic phase for PS could begin directly with HT.
#Only those people who underwent gonadectomy.
transwomen applied for treatment in 2015. This change in sex ratio was mainly due to the increase in adolescent transgender boys, because the ratio of transwomen to transmen in adults remained stable over time.

**Prevalence and Treatment**

At the end of 2015, 3,838 transgender people at least 16 years old had received medical treatment and were not deceased. Because the total population of people at least 16 years old in the Netherlands in 2015 was 13,870,426, the prevalence was 27.7 per 100,000 people (95% CI = 26.8–28.6), or 1:3,600. Stratification for transwomen and transmen showed a prevalence of 36.4 (95% CI = 35.0–37.8) per 100,000 people (or 1:2,800) for men (transwomen) and 19.3 (95% CI = 18.3–20.3) per 100,000 people (or 1:5,200) for women (transmen). The calculation of prevalence numbers of people at least 12 years old and specific age groups are presented in Table 3.

The percentage of adult people who started HT within 5 years after the 1st visit decreased over time, whereas the percentage of people who underwent gonadectomy within 5 years after starting HT remained stable (Figure 2). Of the total study population at least 18 years old treated with HT for at least 1.5 years, 75.6% of transwomen (n = 1,742) and 82.4% of transmen (n = 885) underwent gonadectomy. The median time from the 1st visit to the start of HT for adults was 327 days (IQR = 36–570 days) and from the 1st visit to gonadectomy was 1,029 days (IQR = 679–1,465 days). The median follow-up time for people treated with HT was 6.4 years (range = 0.4–41.6 years).

Of adolescents, 41.0% started PS, whereas only 1.9% of these adolescents stopped PS and did not start HT (Table 1). 32.2% of adolescents started directly with HT, because they were too old (>18 years) to start with PS after the diagnostic phase.

**Regret**

Regret was identified in 0.6% of transwomen and 0.3% of transmen who underwent gonadectomy. The characteristics of these people are presented in Table 4. Their ages at start of HT ranged from 25 to 54 years, and they expressed their regrets 46 to 271 months after initiation of HT. Reasons for regret were divided into social regret, true regret, or feeling non-binary. Transwomen who were classified as having social regret still identified as women, but reported reasons such as “ignored by surroundings” or “the loss of relatives is a large sacrifice” for returning to the male role. People who were classified as having true regret reported that they thought gender-affirming treatment would be a “solution” for, for example, homosexuality or personal acceptance, but, in retrospect, regretted the diagnosis and treatment.

**DISCUSSION**

The aim of this study was to generate a dataset of all individuals who presented to our clinic for gender-affirming care from 1972 to 2015. We found that the number of people with
gender identity issues who sought professional help increased dramatically in recent decades and that the median age of adults at presentation decreased. The ratio of transwomen to transmen remained stable over the years for adults, whereas in adolescents the population of transgender boys increased compared with the population of transgender girls. Currently, more transgender boys than transgender girls are seen. This phenomenon also has been described by Aitken et al.17 The age at the 1st visit was

Table 3. Prevalence numbers, specified for different age groups*

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Total population</th>
<th>Male sex assigned at birth (transwomen)</th>
<th>Female sex assigned at birth (transmen)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Per 100,000</td>
<td>1 per</td>
<td>Per 100,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Per 100,000</td>
</tr>
<tr>
<td>≥12</td>
<td>26.9 (26.1–27.8)</td>
<td>3,700</td>
<td>19.3 (18.3–20.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5,200</td>
</tr>
<tr>
<td>≥16</td>
<td>27.7 (26.8–28.6)</td>
<td>3,600</td>
<td>19.3 (18.3–20.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5,200</td>
</tr>
<tr>
<td>12–18</td>
<td>27.0 (13.9–18.4)</td>
<td>6,300</td>
<td>21.0 (17.7–25.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4,800</td>
</tr>
<tr>
<td>18–30</td>
<td>35.7 (33.5–38.2)</td>
<td>2,800</td>
<td>41.4 (37.9–45.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2,400</td>
</tr>
<tr>
<td>30–50</td>
<td>30.5 (29.0–32.2)</td>
<td>3,300</td>
<td>21.0 (19.2–23.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4,800</td>
</tr>
<tr>
<td>≥50</td>
<td>23.0 (21.9–24.2)</td>
<td>4,300</td>
<td>9.7 (8.7–10.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10,300</td>
</tr>
</tbody>
</table>

*Data are presented as number (95% CI).
older for adult transwomen than for transmen. The percentage of adult people starting HT within 5 years after the 1st visit decreased over time, whereas the percentage of people who underwent gonadectomy within 5 years after starting HT remained stable. Of the total population treated with HT, 77.8% underwent a gonadectomy. Only a very small percentage of people who underwent gonadectomy regretted their decision, expressed as the start of HT in line with their sex assigned at birth.

An explanation for the increase in referrals could be the increased attention in society and media, which contributes not only to awareness of the existence of GD and possibilities for medical treatment but also to greater social acceptance. In addition, information about transgender identities has become much more accessible through the internet within the past decade, which could lead to an earlier recognition of gender identity issues. Also, transgender and gender non-binary individuals might be more willing to access care and more access to care has become available.

The increase in the prevalence of people with GD who sought medical treatment in the Netherlands (1:11,900 transwomen and 1:30,400 transmen in 1990 vs 1:2,800 transwomen and 1:5,200 transmen currently) suggests that the transgender population is dramatically increasing. The highest prevalence for transwomen was found for the 30- to 50-year age group (1:2,500), whereas that for transmen was found in the 18- to 30-year age group (1:2,400). Transgender people in the Netherlands seem to experience a reasonable degree of acceptance owing to a tolerant social climate in contrast to many other countries. For example, medical costs are reimbursed by medical insurance companies, and it is possible to change the legal sex status (even without gonadectomy). These points can lead to a lower threshold to seek help, making this study population useful for an adequate estimation of the current prevalence of people with GD who seek medical treatment. More than 95% of transgender people are treated in our gender identity clinic. However, not all transgender people seek medical help. Some use self-medication or go abroad for treatment. Therefore, these numbers might still be an underestimation of the real prevalence. Our data represent a population that actively sought help in a medical setting. In 2012, a Dutch study of non-clinical people reported that 0.6% (1:167) of those with male sex assigned at birth and 0.2% (1:500) of those with female sex assigned at birth reported an incongruent gender identity with a wish for hormones or surgery. However, that was a population-based study with a response rate of 20.9%, which could lead to non-response bias. In addition, the existence of incongruent gender identities was based on self-report and no detailed assessment of GD was performed, which could have led to higher prevalence rates.

An interesting finding is the percentage of children who were referred in childhood (before 12 years of age) and who started PS when the GD persisted and the eligibility criteria were fulfilled. This 40% of children who started PS is almost identical to the 39% of persistence of childhood GD reported in a previous study.
Dutch study (using a smaller cohort of children). In addition, the finding that the persistence is higher in natal girls (49.1%) compared with natal boys (33.6%) is in line with observations in previous follow-up studies on the persistence of GD in children (for an overview, see Ristori and Steensma).

Remarkably, we found a decrease over time in the percentage of referred adult people who actually started HT. This finding might be explained by the fact that in the past it was harder to find information about GD and its treatment, and only people with extreme types of GD managed to visit our gender identity clinic for treatment. Currently, owing to media attention and the internet, it is easier to access information about our gender identity clinic, making the threshold lower to search for help. This could have led to referrals of people with milder forms of GD and people who were not sure of their feelings and just wanted to explore these with a psychologist. Such people eventually might not pursue HT. Another explanation might be that not all transgender people want to undergo HT, such as transmen or people with a non-binary identity who only want a mastectomy.

By contrast, we noticed that the percentage of people who underwent gonadectomy within 5 years after the start of HT remained stable over time. At the start of the clinic in 1972, knowledge about transgender care was limited and only people who wished for a classic treatment, consisting of a diagnostic phase, HT plus social transitioning, and surgery (in this order), were treated. There was no room for partial treatments. Since the publication of the Standards of Care Version 6 in 2001, other types of treatment are offered. In addition, in 2014, a change in Dutch law allowed transgender people without a wish to undergo gonadectomy to alter the sex on their birth certificate with a statement of an expert who declared that the individual was diagnosed with GD (Dutch civil law, article 1:28). Although these changes in clinical guidelines and the law might have led to a decrease in the number of transgender people choosing gonadectomy, the current results do not show this. However, the follow-up time of this study might be too short to notice such changes.

In the HT group, 22% of people who were eligible for surgery had not undergone gonadectomy. These numbers are...
centers or people with regret.

Despite the large increase in treated transgender people, the percentage of people who underwent gonadectomy but regretted their decision was still very small (0.5%). In a review by Pfäfflin, regrets were reported by less than 1% of transmen and 1% to 1.5% by transwomen after gonadectomy. More recent studies have reported regret percentages of 0% to 2% and 6% after gonadectomy. 13 of the 14 people who regretted gonadectomy had started HT from 1978 through 1997 and started in 2004. At best, this indicates that the diagnostic and eligibility criteria for treatment have improved over the past decade. Another explanation might be the altered treatment protocol, which also allowed people to receive HT without gonadectomy. Our findings could be an underestimation of people with regret after gonadectomy, because some might choose to go elsewhere for reversal therapy or might experience regret without pursuing reversal surgery or HT. Regret might not always result in a desire for reversal therapy, as it may be hidden from others. In addition, in our population the average time to regret was 130 months, so it might be too early to examine regret rates in people who started with HT in the past 10 years.

The Center of Expertise on Gender Dysphoria of the VUmc Amsterdam is the largest gender identity clinic in the Netherlands, where people of all ages, including children and adolescents, are treated. Life-time follow-up is recommended, making it a useful study population for collection of epidemiologic data and future long-term studies of treatment effects. However, there are some limitations. Because this is a retrospective chart review study, some data could be lacking. (i) Some people who once visited our clinic might not be reported in our database. However, we used several search strategies to identify the total study population, thereby decreasing the possibility of missing people. (ii) A large number of transgender people who had initially received treatment in our center were lost to follow-up. Although transgender people receive lifelong care, a large group (36%) did not return to our clinic after several years of treatment. Therefore, we could have missed some information on, for example, gonadectomies performed at other centers or people with regret.

CONCLUSIONS

We found that the prevalence of treated transgender people increased exponentially. Because of this growing population, it is necessary that health care providers outside university clinics also have knowledge about GD and its treatment, because HT can influence the course of several diseases and interact with several types of medication. We also found that of all transgender people treated with HT, approximately 22% kept their gonads in situ. These people require special attention, because the long-term effects of HT on the testes, ovaries, and uterus are not established. These topics and other possible complications, such as cancer risks, are subjects for further research.

ACKNOWLEDGMENT

The authors would like to thank Jos A.J. Megens for his role in accurate administrative work which helped us defining the study population.

Corresponding Author: M. den Heijer, MD, PhD, Department of Internal Medicine, Section Endocrinology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands. Tel: +31-20-444-0530; Fax: +31-20-444-4313; E-mail: m.denheijer@vumc.nl

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

STATEMENT OF AUTHORSHIP

Category 1

(a) Conception and Design
C.M. Wiepjes; N.M. Nota; C.J.M. de Blok; M. Klaver; R.T. de Jongh; P. Cohen-Kettenis; L.J.G. Gooren; B.P.C. Kreukels; M. den Heijer

(b) Acquisition of Data
C.M. Wiepjes; N.M. Nota; C.J.M. de Blok; M. Klaver; T.D. Steensma; B.P.C. Kreukels

(c) Analysis and Interpretation of Data
C.M. Wiepjes; N.M. Nota; C.J.M. de Blok; M. Klaver; A.L.C. de Vries; S.A. Wensing-Kruger; R.T. de Jongh; M. Bouman; T.D. Steensma; P. Cohen-Kettenis; L.J.G. Gooren; B.P.C. Kreukels; M. den Heijer

Category 2

(a) Drafting the Article
C.M. Wiepjes; N.M. Nota; P. Cohen-Kettenis; L.J.G. Gooren; B.P.C. Kreukels

(b) Revising It for Intellectual Content
N.M. Nota; C.J.M. de Blok; M. Klaver; A.L.C. de Vries; S.A. Wensing-Kruger; R.T. de Jongh; M. Bouman; T.D. Steensma; P. Cohen-Kettenis; L.J.G. Gooren; B.P.C. Kreukels; M. den Heijer

Category 3

(a) Final Approval of the Completed Article
C.M. Wiepjes; N.M. Nota; C.J.M. de Blok; M. Klaver; A.L.C. de Vries; S.A. Wensing-Kruger; R.T. de Jongh; M. Bouman; T.D. Steensma; P. Cohen-Kettenis; L.J.G. Gooren; B.P.C. Kreukels; M. den Heijer

REFERENCES

Amsterdam Cohort of Gender Dysphoria Study


